share_log
  • 要聞
  • 證券新聞網啟動對克洛維斯腫瘤科的覆蓋 (NASDAQ: CLVS)

StockNews.com Initiates Coverage on Clovis Oncology (NASDAQ:CLVS)

StockNews.com Initiates Coverage on Clovis Oncology (NASDAQ:CLVS)

證券新聞網啟動對克洛維斯腫瘤科的覆蓋 (NASDAQ: CLVS)
Defense World ·  2022/12/19 16:11

Analysts at StockNews.com began coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research note issued to investors on Monday. The firm set a "hold" rating on the biopharmaceutical company's stock.

斯托克新聞網的分析師在週一發佈給投資者的一份研究報告中開始報道克洛維斯腫瘤公司(納斯達克代碼：CLVS-GET Rating)的股票。該公司對這家生物製藥公司的股票設定了“持有”評級。

Separately, JPMorgan Chase & Co. downgraded Clovis Oncology from a "neutral" rating to an "underweight" rating in a research report on Wednesday, November 9th.

另外，摩根大通公司在11月9日星期三的一份研究報告中將Clovis Oncology的評級從中性下調至減持。

Get
到達
Clovis Oncology
克洛維斯腫瘤學
alerts:
警報：

Clovis Oncology Stock Down 18.5 %

克洛維斯腫瘤學股票下跌18.5%

CLVS stock opened at $0.08 on Monday. The firm has a market capitalization of $11.60 million, a PE ratio of -0.04 and a beta of 0.24. Clovis Oncology has a twelve month low of $0.08 and a twelve month high of $3.32. The stock has a 50-day simple moving average of $0.62 and a two-hundred day simple moving average of $1.16.

CLVS股票週一開盤報0.08美元。該公司市值為1,160萬美元，本益比為-0.04，貝塔係數為0.24。Clovis Oncology的12個月低點為0.08美元，12個月高位為3.32美元。該股的50日簡單移動均線切入位為0.62美元，200日簡單移動均線切入位為1.16美元。

Clovis Oncology (NASDAQ:CLVS – Get Rating) last posted its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.03. The company had revenue of $30.66 million for the quarter, compared to analysts' expectations of $34.79 million. On average, equities research analysts anticipate that Clovis Oncology will post -1.63 EPS for the current fiscal year.
克洛維斯腫瘤公司(納斯達克代碼：CLVS-GET Rating)最近一次公佈財報是在11月9日星期三。這家生物製藥公司公佈了該季度每股收益(0.39美元)，比分析師普遍預期的(0.42美元)高出0.03美元。該公司當季營收為3,066萬美元，高於分析師預期的3,479萬美元。平均而言，股票研究分析師預計Clovis Oncology本財年的每股收益將達到1.63美元。

Institutional Trading of Clovis Oncology

克洛維斯腫瘤學的機構交易

A number of hedge funds have recently bought and sold shares of CLVS. Vanguard Group Inc. lifted its position in Clovis Oncology by 22.1% in the 1st quarter. Vanguard Group Inc. now owns 12,348,898 shares of the biopharmaceutical company's stock worth $24,945,000 after buying an additional 2,233,797 shares during the last quarter. Millennium Management LLC lifted its position in Clovis Oncology by 49.9% in the 2nd quarter. Millennium Management LLC now owns 5,400,324 shares of the biopharmaceutical company's stock worth $9,721,000 after buying an additional 1,798,313 shares during the last quarter. Renaissance Technologies LLC lifted its position in Clovis Oncology by 139.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,459,900 shares of the biopharmaceutical company's stock worth $2,949,000 after buying an additional 849,500 shares during the last quarter. Palo Alto Investors LP lifted its position in Clovis Oncology by 11.9% in the 1st quarter. Palo Alto Investors LP now owns 4,473,967 shares of the biopharmaceutical company's stock worth $9,037,000 after buying an additional 476,141 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Clovis Oncology by 259.6% in the 3rd quarter. Marshall Wace LLP now owns 310,123 shares of the biopharmaceutical company's stock worth $370,000 after buying an additional 223,880 shares during the last quarter. Institutional investors own 29.47% of the company's stock.

一些對沖基金最近買賣了CLVS的股票。先鋒集團在第一季度將其在Clovis Oncology的地位提高了22.1%。先鋒集團現在持有這家生物製藥公司12,348,898股股票，價值24,945,000美元，在上個季度又購買了2,233,797股。千禧管理公司在第二季度將其在Clovis Oncology的地位提高了49.9%。Millennium Management LLC現在擁有這家生物製藥公司5,400,324股股票，價值9,721,000美元，上個季度又購買了1,798,313股。文藝復興技術公司在第一季度將其在克洛維斯腫瘤學的地位提高了139.2%。復興科技有限責任公司現在擁有這家生物製藥公司1,459,900股票，價值2,949,000美元，在上個季度又購買了849,500股票。Palo Alto Investors LP在第一季度將其在Clovis Oncology的頭寸提高了11.9%。Palo Alto Investors LP現在擁有這家生物製藥公司4,473,967股票，價值9,037,000美元，上個季度又購買了476,141股票。最後，馬歇爾·華斯有限責任公司在第三季度將其在克洛維斯腫瘤學的地位提高了259.6%。馬歇爾·華斯有限責任公司現在持有這家生物製藥公司310,123股股票，價值37萬美元，上個季度又購買了223,880股。機構投資者持有該公司29.47%的股份。

Clovis Oncology Company Profile

Clovis腫瘤學公司簡介

(Get Rating)

(獲取評級)

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Clovis Oncology，Inc.是一家生物製藥公司，專注於在美國、歐洲和國際上收購、開發抗癌藥物並將其商業化。其商業產品包括Rubra(Rucaparib)片劑，這是一種小分子聚ADP-核糖聚合酵素抑制劑，用於單一療法治療與惡性BRCA突變相關的晚期卵巢癌患者，這些患者已接受兩種或兩種以上化療，並由FDA批准的Rubra輔助診斷選擇進行治療。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
  • How Do Chipmakers Stack Up When It Comes To Growth?
  • Is AMC Entertainment Stock Worth Taking Down Here?
  • Is it Time to Take a Bite into Domino's Pizza?
  • MarketBeat: Week in Review 12/12 – 12/16
  • Which Two Bluechip Tech Companies Have Raised Their Guidance?
  • 免費獲取StockNews.com關於克洛維斯腫瘤學(CLVS)的研究報告
  • 當談到增長時，晶片製造商是如何提升的？
  • AMC娛樂股票值得在這裡下跌嗎？
  • 是時候去Domino‘s Pizza嘗一口了嗎？
  • MarketBeat：回顧一週12/12-12/16
  • 哪兩家藍籌科技公司提高了他們的指引？

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

接受Clovis腫瘤學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Clovis Oncology和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間